Navigation Links
Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
Date:11/17/2010

RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS. The data from study SB-509-801 demonstrated that the drug was well-tolerated in subjects with ALS and that 40% of SB-509 treated subjects had delayed deterioration of toe and ankle muscle strength as measured by manual muscle testing (MMT) compared to 23% of baseline-matched historic controls.  In addition, positive improvements in electrophysiological measures of motor nerves were observed in a subset of treated subjects.  The data were presented at the Society for Neuroscience Annual Meeting which is being held in San Diego.  

"These data are consistent with the delay in muscle deterioration that we have observed in both preclinical models of ALS as well as in clinical studies of this drug in subjects with diabetic neuropathy, a condition that is also characterized by degeneration and deterioration of nerve function," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our primary aim in this trial was to assess safety and tolerability of treatment with SB-509 in this vulnerable patient population and to conduct a signal-seeking study in which we assessed the effect of treatment on several clinical measures of function in ALS.  As this was an early-stage trial, for safety reasons we treated subjects twice over a 90 day period, although our positive preclinical animal data were achieved with a more frequent dosing schedule.  With that said, the delayed deterioration in muscle strength in the ankle and toe are very encouraging and may reflect the importa
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
3. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
4. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
7. Sangamo Announces Closing of Common Stock Offering
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... Aug. 22, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... launch and availability of ONSOLIS (fentanyl buccal soluble film) ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is approved in ... be marketed as BREAKYL) for the management of breakthrough ...
... the Food and Drug Administration (FDA) approved Seattle Genetics, ... – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). ... approved for Hodgkin lymphoma patients after failure of a ... ALCL patients after failure of at least one multi-agent ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The excitement is building ... Mount Airy, North Carolina. This year the Surry Arts Council ... people from around the country who are still fans of the ... is a sitcom that aired on CBS from 1960 through 1968. ... show in American television history. Mount Airy, North Carolina is ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... and high-school students who bully their classmates are more likely ... marijuana, a new study found. Researchers found that bullies ... were more likely to use substances than were victims ... behavior may be related to another," said Kisha Radliff, lead ...
... (March 5, 2012) Chinese Minister of Health, Dr. Zhu ... researchers from across the U.S. and China with the goal ... and creating deeper ties to fast-track cancer research. The ... renowned cancer experts, designed to develop a framework for future ...
... -- Vitamin E may stimulate cells that result in ... by Shu Takeda of Keio University in Tokyo said ... vitamin E supplements. The researchers explain that maintaining ... (osteoclasts) keeps bones strong. Although prior studies had suggested ...
... , MONDAY, March 5 (HealthDay News) -- Babies ... greater risk of developing asthma when compared with children born ... to infants born between the 34th and 37th week of ... an asthma diagnosis by the age of 8 years, despite ...
... March 2012: Each year over 4.3 million people ... yet many of these deaths might have been prevented ... smoking cessation, weight loss, improved diets and increased ... interventions will be presented, together with cutting-edge research on ...
... Fla. Researchers have identified a gene that causes adult-onset ... twist involuntarily. The discovery by a team from the Jacksonville, ... Health Sciences Center sheds light on a movement disorder that ... Annals of Neurology . In 1990, ...
Cached Medicine News:Health News:School bullies more likely to be substance users, study finds 2Health News:School bullies more likely to be substance users, study finds 3Health News:Chinese Minister of Health to hold US meeting to improve cancer research collaboration 2Health News:Mouse Study Suggests Vitamin E May Weaken Bones 2Health News:Late Preemie Birth May Be Linked to Higher Asthma Risk 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 3Health News:EuroPRevent2012, the premier international forum for preventive cardiology 4Health News:EuroPRevent2012, the premier international forum for preventive cardiology 5Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 3
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: